HK Stock Market Move | GENFLEET-B(02595) rose by more than 6% in the closing session. The clinical research results of two new drugs under development will be presented at the 2026 ASCO Annual Meeting.

GENFLEET-B (02595) rose more than 6% in the final trading session, rising 6.26% to HK$34.28 by the time of this report, with a trading volume of HK$44.4851 million. On the news front, Genfeng Pharmaceutical announced that the clinical research results of two investigational new drugs will be presented at the 2026 ASCO Annual Meeting. Among them, the research data for the treatment of KRAS G12D mutation cholangiocarcinoma and colorectal cancer with GFH375 as a monotherapy were selected for oral presentation. This study will be the first to release specialized clinical data on RAS inhibitors for the treatment of cholangiocarcinoma in the industry, and will demonstrate the preliminary efficacy of GFH375 in the treatment of cholangiocarcinoma and colorectal cancer. In addition, the clinical data of the world's first cachexia bispecific antibody GFS202A will also be presented for the first time in the poster section of the ASCO Annual Meeting. It is worth noting that on May 25th, the official website of the Drug Clinical Trial Registration and Information Disclosure Platform showed that Genfeng Pharmaceutical has registered a randomized, open-label, multicenter Phase III clinical study to evaluate GFH375 versus docetaxel in participants with locally advanced unresectable or metastatic non-small cell lung cancer who have failed previous standard treatment and have the KRASG12D mutation.